Cardiology Division, Department of Medicine, New York Medical College/Westchester Medical Center, Macy Pavilion, Room 141, Valhalla, NY, 10595, USA.
Curr Hypertens Rep. 2017 Aug;19(8):67. doi: 10.1007/s11906-017-0764-8.
The goal is to discuss management of hypertension in the elderly.
At 3.14-year follow-up of 2636 persons ≥75 years in the Systolic Blood Pressure Intervention Trial (SPRINT), compared with a systolic blood pressure (SBP) goal of <140 mmHg, a SBP goal of <120 mmHg reduced the primary endpoint of myocardial infarction, other acute coronary syndrome, stroke, heart failure, or cardiovascular death by 34% (p = 0.001), all-cause mortality by 33% (p = 0.009), heart failure by 38% (p = 0.003), and the primary outcome or death by 32% (p < 0.001). Absolute cardiovascular event rates were lower for the intensive treatment group within each frailty stratum. The incidence of serious adverse events was similar in both treatment groups. The SPRINT trial provides very important information on the efficacy and safety of lowering the SBP to <120 mmHg in elderly adults with hypertension.
讨论老年人高血压的管理。
在收缩压干预试验(SPRINT)中,对 2636 名年龄≥75 岁的患者进行了 3.14 年的随访,与收缩压(SBP)目标<140mmHg 相比,SBP 目标<120mmHg 使心肌梗死、其他急性冠状动脉综合征、卒中等主要终点降低了 34%(p=0.001),全因死亡率降低了 33%(p=0.009),心力衰竭降低了 38%(p=0.003),主要结局或死亡降低了 32%(p<0.001)。在每个虚弱分层内,强化治疗组的绝对心血管事件发生率较低。两组治疗的严重不良事件发生率相似。SPRINT 试验提供了关于将高血压老年患者的 SBP 降低至<120mmHg 的疗效和安全性的非常重要的信息。